CI Investments Inc. Buys 203,455 Shares of Hims & Hers Health, Inc. $HIMS

CI Investments Inc. increased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 6,659.7% during the 3rd quarter, Holdings Channel.com reports. The fund owned 206,510 shares of the company’s stock after purchasing an additional 203,455 shares during the quarter. CI Investments Inc.’s holdings in Hims & Hers Health were worth $11,713,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after buying an additional 78,543 shares during the period. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health during the first quarter valued at about $30,000. Envestnet Asset Management Inc. boosted its holdings in shares of Hims & Hers Health by 41.8% during the second quarter. Envestnet Asset Management Inc. now owns 83,844 shares of the company’s stock worth $4,180,000 after purchasing an additional 24,726 shares during the period. Bessemer Group Inc. grew its stake in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its stake in shares of Hims & Hers Health by 26.5% in the second quarter. Teacher Retirement System of Texas now owns 33,018 shares of the company’s stock worth $1,646,000 after purchasing an additional 6,925 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Activity

In other news, insider Deborah M. Autor sold 7,054 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the sale, the insider directly owned 6,175 shares of the company’s stock, valued at $226,684.25. The trade was a 53.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 82,963 shares of company stock valued at $2,944,621. 17.71% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of several research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. BTIG Research lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th. TD Cowen cut their target price on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a research note on Tuesday, February 24th. Leerink Partners reduced their price target on shares of Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating on the stock in a research report on Tuesday, February 24th. Finally, Deutsche Bank Aktiengesellschaft set a $31.00 price target on shares of Hims & Hers Health and gave the stock a “hold” rating in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $32.27.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $15.78 on Wednesday. The company’s fifty day moving average price is $25.85 and its 200-day moving average price is $38.63. The stock has a market cap of $3.60 billion, a PE ratio of 30.94, a price-to-earnings-growth ratio of 3.16 and a beta of 2.55. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. Hims & Hers Health’s revenue was up 28.4% on a year-over-year basis. During the same period last year, the company posted $0.11 EPS. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has initiated a share buyback program on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.